HIV-1 reverse transcriptase gene 103K/N and 184M/V combinations in tandem: Detection and quantification of HIV-1 populations in the CD45RO+ T-cell compartment by a double-ARMS real-time PCR assay

Journal of Acquired Immune Deficiency Syndromes

Volumn 41, Issue 2, 2006, Pages 160-167

  Mohey, Rajesh ^a   Tolstrup, Martin ^a   Jørgensen, Louise B ^b   Møller, Bjarne K ^a   Black, Finn T ^a   Kjems, Jørgen ^c   Obel, Niels ^d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Statens Seruminstitut ^*  (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

103K N; 184M V; CD45RO+ T cell compartment; HIV drug resistance resistance mutations; Mutations in tandem

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD45RO ANTIGEN; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; TENOFOVIR; ZIDOVUDINE; CD45 ANTIGEN; OXAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CODON; DEMOGRAPHY; DNA EXTRACTION; FEMALE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MALE; MEMORY T LYMPHOCYTE; MONOTHERAPY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROVIRUS; REAL TIME POLYMERASE CHAIN REACTION; SEXUAL TRANSMISSION; T LYMPHOCYTE; VIREMIA; VIRUS DETECTION; VIRUS GENE; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS TITRATION; WILD TYPE; CROSS-SECTIONAL STUDY; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; VIROLOGY;

ADULT; AGED; ANTIGENS, CD45; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; GENES, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; IMMUNOLOGIC MEMORY; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; NEVIRAPINE; OXAZINES; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; T-LYMPHOCYTES; VIRAL LOAD;

EID: 33645320316     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000191998.70034.64     Document Type: Article

References (42)

1. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117-122.
2. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
3. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science. 1988;242:1171-1173.
4. Chun TW, Finzi D, Margolick J, et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med. 1995;1:1284-1290.
5. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-517.
6. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9:727-728.
7. Persaud D, Zhou Y, Siliciano JM, et al. Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol. 2003;77:1659-1665.
8. Ruff CT, Ray SC, Kwon P, et al. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol. 2002;76:9481-9492.
9. Metzner KJ, Bonhoeffer S, Fischer M, et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis. 2003;188:1433-1443.
10. Charpentier C, Dwyer DE, Mammano F, et al. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol. 2004;78:4234-4247.
11. Brenner BG, Routy JP, Petrella M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol. 2002;76:1753-1761.
12. Barbour JD, Hecht FM, Wrin T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS. 2004;18:1683-1689.
13. Lambotte O, Chaix ML, Gubler B, et al. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS. 2004;18:1147-1158.
14. Nunberg JH, Schleif WA, Boots EJ, et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol. 1991;65:4887-4892.
15. Kavlick MF, Shirasaka T, Kojima E, et al. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (- -)-2′,3′-dideoxy-3′-thiacytidine. Antiviral Res. 1995;28:133-146.
16. Tisdale M, Kemp SD, Parry NR, et al. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA. 1993;90:5653-5656.
17. Bacheler LT. Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase. Drug Resist Updat. 1999;2:56-67.
18. Deeks SG. International perspectives on antiretroviral resistance: non-nucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr. 2001;26(Suppl 1):S25-S33.
19. Miller V, de Bethune MP, Kober A, et al. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother. 1998;42:3123-3129.
20. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologie failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. JAMA. 2000;283:205-211.
21. Gunthard HF, Wong JK, Ignacio CC, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol. 1998;72:2422-2428.
22. Miller V, Stark T, Loeliger AE, et al. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Med. 2002;3:135-145.
23. Sharma PL, Crumpacker CS. Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudrne-selected Met184Val. J Virol. 1999;73: 8448-8456.
24. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994;68:1660-1666.
25. Domaoal RA, Demeter LM. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors. Int J Biochem Cell Biol. 2004;36:1735-1751.
26. Eisenberg S, Aksentijevich I, Deng Z, et al. Diagnosis of familial Mediterranean fever by a molecular genetics method. Ann Intern Med. 1998;129:539-542.
27. Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA: the amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17:2503-2516.
28. Wenham PR, Newton CR, Price WH. Analysis of apolipoprotein E genotypes by the Amplification Refractory Mutation System. Clin Chem. 1991;37:241-244.
29. Lo YM, Patel P, Newton CR, et al. Direct haplotype determination by double ARMS: specificity, sensitivity and genetic applications. Nucleic Acids Res. 1991;19:3561-3567.
30. + T cells of patients on HAART with a viremia less than 1000 copies/ml. J Clin Virol. 2005 (in press).
31. Hance AJ, Lemiale V, Izopet J, et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol. 2001;75:6410-6417.
32. Palmer S, Kearney M, Maldarelli F, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005;43:406-413.
33. Delaugerre C, Morand-Joubert L, Chaix ML, et al. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther. 2004;9:415-421.
34. Dykes C, Najjar J, Bosch RJ, et al. Detection of drug-resistant minority variants of HIV-1 during virologie failure of indinavir, lamivudine, and zidovudine. J Infect Dis. 2004;189:1091-1096.
35. Paolucci S, Baldanti F, Zavattoni M, et al. Novel recombinant phenotypic assay for clonal analysis of reverse transcriptase mutations conferring drug resistance to HIV-1 variants. J Antimicrob Chemother. 2004;53:766-771.
36. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 2005;293:817-829.
37. Boucher CA, Cammack N, Schipper P, et al. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1993;37:2231-2234.
38. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995;269:696-699.
39. Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther. 1999;4:87-94.
40. Jonckheere H, Witvrouw M, De CE, et al. Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1. AIDS Res Hum Retroviruses. 1998;14:249-253.
41. Diallo K, Brenner B, Oliveira M, et al. The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates. Antimicrob Agents Chemother. 2003;47:2376-2379.
42. Ross L, Parkin N, Chappey C, et al. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. AIDS. 2004;18:1691-1696.